Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
466-01-010 ISMRM Abstract

Histogram Analysis of DKI for T Restaging and Predicting pCR of LARC Following Following Neoadjuvant Immunotherapy

Primary: Diffusion - DWI/DTI/DKI
Secondary: Body - Pelvis
466-01-010 · Rectal Cancer · Tuesday, 12 May, 8:20 AM–9:15 AM · Digital Posters Row G
Keywords: Diffusion kurtosis imaging Locally advanced rectal cancer Pathological complete response T restaging Neoadjuvant Immunotherapy
Accepted
Xin Li 1, Ziwei Jin1, Na Hao1, Peng Sun2, Ning Zheng3,4, Lan Zhang1
1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan 430022, Hubei Province, China
2Institute of Research and Clinical Innovations, Neusoft Medical Systems Co. Ltd, Shenyang, China
3Philips Healthcare (Beijing), Beijing, China
4Clinical and Technical Support, Philips Healthcare (Beijing), Beijing, China
Presenting Author: Xin Li

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(10):1139-67.
2. Shin J, Seo N, Baek SE, Son NH, Lim JS, Kim NK, et al. MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemoradiotherapy. Radiology. 2022;303(2):351-8.
3. Smith FM, Cresswell K, Myint AS, Renehan AG. Is "watch-and-wait" after chemoradiotherapy safe in patients with rectal cancer? Bmj. 2018;363:k4472.
4. Corrò C, Dutoit V, Koessler T. Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers (Basel). 2021;13(6).
5. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436-43.
6. Wang Y, Shen L, Wan J, Zhang H, Wu R, Wang J, et al. Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation. Front Immunol. 2022;13:1067036.
7. Lin ZY, Zhang P, Chi P, Xiao Y, Xu XM, Zhang AM, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Ann Oncol. 2024;35(10):882-91.
8. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40(23):2546-56.
9. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De Schutter H, et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys. 2006;65(1):246-54.
10. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441-6.
11. Jensen JH, Helpern JA, Ramani A, Lu H, Kaczynski K. Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging. Magn Reson Med. 2005;53(6):1432-40.
12. Wen Z, Chen Y, Yang X, Lu B, Liu Y, Shen B, et al. Application of magnetic resonance diffusion kurtosis imaging for distinguishing histopathologic subtypes and grades of rectal carcinoma. Cancer Imaging. 2019;19(1):8.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/466-01-010